NAD+ และ IV Vitamin Therapy: สิ่งที่วิทยาศาสตร์แสดงจริงๆ (และสิ่งที่ไม่ได้แสดง)

NAD+ คืออะไร — ชีววิทยาที่ไม่มีข้อโต้แย้ง

ระดับ NAD+ ลดลงจริงตามอายุหรือไม่? หลักฐานยังเป็นที่ถกเถียง

~ น่าจะเป็นจริง (หลักฐานไม่สมบูรณ์)

ระดับ NAD+ ลดลงอย่างสากลตามอายุในเนื้อเยื่อมนุษย์ — ข้อสมมติฐานหลักที่ใช้เป็นเหตุผลในการเสริมอาหาร

🅰 'Age-Dependent Decline of NAD+—Universal Truth or Confounded Consensus?' — PMC8747183 (2022 critical review)— A 2022 peer-reviewed critical review found that 'despite systematic claims of overall changes in NAD+ levels with aging, the evidence to support such claims is very limited.' Only two studies had directly measured NAD+ in human tissues during normal aging. Measurement estimates varied from no change to 80–90% reduction depending on method and tissue. The review concluded that larger, longitudinal studies are needed before decline can be called a 'universal truth.' The decline is better established in animal studies and in specific human tissues than as a generalised human fact.

สารตั้งต้น NAD+ แบบรับประทาน (NMN / NR): สิ่งที่การทดลองในมนุษย์แสดง

✓ พิสูจน์แล้ว

การเสริม NMN แบบรับประทานเพิ่มความเข้มข้นของ NAD+ ในเลือดมนุษย์

🅰 'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)— Consistent finding across trials: blood NAD+ rises 1–2.5 fold. This is a pharmacokinetic measurement, not a clinical outcome. Rising blood NAD+ does not establish that target tissues benefit, or that health outcomes improve.

~ น่าจะเป็นจริง (หลักฐานไม่สมบูรณ์)

การเสริม NMN แบบรับประทานมีความปลอดภัยในผู้ใหญ่ที่สุขภาพดีในขนาดที่ทดสอบในการทดลองระยะสั้น

🅰 'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)— No serious adverse events in published trials. However, most studies were short (weeks to a few months) and small (n=8–66). Long-term safety is not established.

✗ ไม่พบหลักฐาน

การเสริม NMN แบบรับประทานย้อนกลับการแก่ชรา ยืดอายุ หรือฟื้นฟูการทำงานของเซลล์ในผู้ใหญ่ที่มีสุขภาพดีอย่างมีความหมาย

🅰 'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)— No human trial has tested longevity or anti-aging outcomes at sufficient scale or duration. Individual signals (e.g., improved muscle function, insulin sensitivity in small cohorts) have been reported but not replicated in well-powered trials. The review authors explicitly caution against confident efficacy claims.

IV NAD+: สิ่งที่เกิดขึ้นจริงเมื่อฉีดเข้าหลอดเลือด

✗ ไม่พบหลักฐาน

IV NAD+ เข้าสู่เซลล์โดยตรงและเติมเต็มแหล่งเก็บ NAD+ ในเซลล์ ซึ่งเป็นเหตุผลข้อได้เปรียบเหนือการเสริมแบบรับประทาน

🅰 'A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+' — PMC6751327 (2019, n=11)— The pilot study found that IV NAD+ is rapidly degraded by circulating enzymes into metabolites (nicotinamide, ADPR). Whether those breakdown products are later taken up by cells and reconverted to NAD+ is biologically plausible (the 'breakdown and salvage' hypothesis) but has not been demonstrated in human tissue. The assumption that IV provides a unique direct cellular benefit over oral precursors is not evidence-based.

✗✗ มีหลักฐานขัดแย้ง

การให้ IV NAD+ ให้ความรู้สึกสบายและทนได้ดี

🅰 'Intravenous infusion of NAD+ versus NR: a retrospective tolerability pilot study in a real-world setting' — PMC12907335 (Frontiers in Aging, 2026, n=14)— A 2026 retrospective study at a commercial wellness clinic found that all 6 participants who received IV NAD+ reported moderate-to-severe abdominal cramping, diarrhoea, nausea, vomiting, increased heart rate, chest pressure, and throat pain during the infusion. Symptoms resolved on completion. NR IV was better tolerated but still caused tingling and mild cramping. Sample size was very small (n=14 total), and no placebo group was used.

IV Vitamin Drips โดยกว้าง: หลักฐาน Myers' Cocktail

✗ ไม่พบหลักฐาน

การให้ Myers' Cocktail ทางหลอดเลือดดำให้ผลลัพธ์ที่ดีกว่า placebo อย่างมีนัยสำคัญในมนุษย์

🅰 'Intravenous Micronutrient Therapy (Myers' Cocktail) for Fibromyalgia: A Placebo-Controlled Pilot Study' — PMC2894814 (2009, n=34, randomised double-blind)— n=34 adults with fibromyalgia. Both treatment and placebo groups improved meaningfully from baseline — a well-documented placebo effect of invasive procedures. No statistically significant difference between groups on any outcome measure. The researchers concluded that efficacy 'relative to placebo remains uncertain.' This is the only RCT for any Myers' Cocktail indication.

✗ ไม่พบหลักฐาน

การให้วิตามินทางหลอดเลือดดำให้ผลลัพธ์สุขภาพที่ดีกว่าการเสริมแบบรับประทานในผู้ใหญ่ที่สุขภาพดี

🅰 CADTH Rapid Review — 'Intravenous Multivitamin Therapy Use in Hospital or Outpatient Settings' (NCBI Bookshelf NBK567072, 2021)— A systematic review (CADTH 2021) searched 396 citations and found no evidence-based guidelines and no high-quality comparative evidence. Recommended future trials comparing IV to oral delivery before any conclusion can be drawn.

สิ่งที่แหล่งอ้างอิงทางการแพทย์กล่าว

ความเสี่ยงที่แท้จริง: สิ่งที่ขั้นตอน IV ทุกอย่างมี

แหล่งข้อมูลทั้งหมด

• 🅰 ปฐมภูมิ

  'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)

  Review of 10 published human NMN trials. Most n=8–66 (Phase I level). Oral supplementation only — no IV data. Blood NAD+ rises confirmed; anti-aging efficacy not established.

• 🅰 ปฐมภูมิ

  'Age-Dependent Decline of NAD+—Universal Truth or Confounded Consensus?' — PMC8747183 (2022 critical review)

  Challenges the widely stated claim. Finds evidence for human NAD+ decline with age is 'very limited,' based on only 2 human tissue studies. Measurement ranges vary enormously. Decline is better established in animal models and specific tissues than as a universal human finding.

• 🅰 ปฐมภูมิ

  'A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+' — PMC6751327 (2019, n=11)

  n=8 treated, 3 control. IV NAD+ was 'rapidly and completely removed from the plasma' within 2 hours — appearing as breakdown products (nicotinamide, ADPR). Whether breakdown products are reconverted to NAD+ in cells is unverified. No adverse events in this small cohort.

• 🅰 ปฐมภูมิ

  'Intravenous infusion of NAD+ versus NR: a retrospective tolerability pilot study in a real-world setting' — PMC12907335 (Frontiers in Aging, 2026, n=14)

  Retrospective; no placebo control; commercial clinic setting. n=6 NAD+ IV, n=8 NR IV. All 6 NAD+ IV participants reported moderate-to-severe cramping, nausea, vomiting, diarrhoea, chest pressure, and throat pain during infusion. Findings are preliminary and cannot establish efficacy.

• 🅰 ปฐมภูมิ

  'Intravenous Micronutrient Therapy (Myers' Cocktail) for Fibromyalgia: A Placebo-Controlled Pilot Study' — PMC2894814 (2009, n=34, randomised double-blind)

  The only published randomised, double-blind, placebo-controlled trial of Myers' Cocktail. No statistically significant difference between treatment and placebo on any outcome. Both groups improved from baseline — consistent with a strong placebo response from the invasive procedure itself.

• 🅱 รองที่น่าเชื่อถือ

  Merck Manual Professional Edition — 'Intravenous Vitamin Therapy (Myers' Cocktail)' (standard clinical reference)

  States: 'insufficient scientific evidence that IV vitamin therapy has any of the above beneficial effects or is effective for treating any disease.' Documents risks including death from infections via improperly sterilised equipment.

• 🅱 รองที่น่าเชื่อถือ

  Cleveland Clinic — 'Intravenous Vitamin Infusion Pros and Cons' (functional medicine specialist commentary)

  Physician-authored. Dr. Melissa Young: 'We're still looking for high-quality studies.' Effectiveness as a general wellness tool described as 'uncertain.' Notes FDA warnings about hydration clinic safety.

• 🅰 ปฐมภูมิ

  CADTH Rapid Review — 'Intravenous Multivitamin Therapy Use in Hospital or Outpatient Settings' (NCBI Bookshelf NBK567072, 2021)

  Systematic review of 396 citations. Found no evidence-based guidelines for IV multivitamin therapy. Conclusion: 'no conclusion can be provided regarding intravenous multivitamin or micronutrient supplementation.' Recommends future RCTs comparing IV to oral delivery.

• 🅰 ปฐมภูมิ

  'To IV or Not to IV: The Science Behind Intravenous Vitamin Therapy' — PMC12182718 (2025 peer-reviewed review)

  Peer-reviewed. Concludes wellness claims are 'primarily anecdotal or based on self-reported outcomes rather than well-designed randomized clinical trials.' Calls for robust long-term RCTs before IV therapy wellness expansion can be justified.